New release allows users to solve problems that were previously out of reach, run more scenarios, and get feasible solutions ...
A novel linear-time algorithm computes left-bounded shortest unique substrings twice as fast as existing methods while ...
Researchers developed a label-partitioned tree decomposition and parameter-separated index that cuts path query latency and ...
A major phase 3 clinical trial was widely expected to confirm the lipoprotein(a) [Lp(a)] hypothesis — that lowering it yields cardiovascular benefit. Harpreet Bhatia, MD When the disappointing results ...
On this date in 1999, Wu-Tang Clan heavyweight Method Man and Def Squad standout Redman joined forces for the release of their first full-length collaborative album, Blackout!, through Def Jam ...
The much-anticipated Lp(a)HORIZON trial testing whether the novel drug pelacarsen can improve cardiovascular outcomes by decreasing lipoprotein(a) levels has failed to meet its primary endpoint.
Novartis’ pelacarsen failed to reduce cardiovascular events despite lowering the harmful cholesterol Lp(a). The setback raises uncertainty for rival experimental Lp(a) drugs from Amgen and Eli Lilly.
Please provide your email address to receive an email when new articles are posted on . Pelacarsen did not reduce cardiovascular events in patients with elevated lipoprotein(a) compared with placebo.
Forbes contributors publish independent expert analyses and insights. Robert Glatter is a New York-based physician covering public health. This voice experience is generated by AI. Learn more. This ...
The result calls into question other late-stage trials testing Lp(a)-lowering drugs from the likes of Amgen and Eli Lilly. (iStock / Getty Images Plus) Novartis’ Ionis-partnered drug designed to lower ...
In a recent Private Equity Law Report article, Dan Oshinsky discussed with PELR the growing use of LP portfolio financing facilities as investors seek alternative sources of liquidity amid a continued ...